Equities Analysts Offer Predictions for SWTX FY2027 Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Investment analysts at Wedbush cut their FY2027 EPS estimates for SpringWorks Therapeutics in a report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $3.42 for the year, down from their prior estimate of $3.47. Wedbush currently has a “Outperform” rating and a $77.00 target price on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.12) per share.

A number of other research firms have also weighed in on SWTX. HC Wainwright lowered their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Evercore ISI assumed coverage on shares of SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Guggenheim cut their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $70.00.

SpringWorks Therapeutics Trading Up 3.0 %

SWTX opened at $33.48 on Wednesday. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -8.63 and a beta of 0.82. SpringWorks Therapeutics has a 12-month low of $28.21 and a 12-month high of $53.92. The business’s fifty day simple moving average is $37.97 and its 200-day simple moving average is $36.40.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analysts’ expectations of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. SpringWorks Therapeutics’s revenue was up 4810.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.27) earnings per share.

Institutional Investors Weigh In On SpringWorks Therapeutics

Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after purchasing an additional 474 shares in the last quarter. Quantbot Technologies LP purchased a new position in SpringWorks Therapeutics during the 3rd quarter worth $147,000. Quarry LP increased its position in SpringWorks Therapeutics by 56.3% during the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock valued at $188,000 after buying an additional 1,800 shares in the last quarter. Park Avenue Securities LLC purchased a new stake in SpringWorks Therapeutics in the fourth quarter valued at about $203,000. Finally, Commerce Bank acquired a new stake in SpringWorks Therapeutics in the third quarter worth about $207,000.

Insider Buying and Selling at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total value of $839,400.00. Following the transaction, the chief operating officer now owns 209,600 shares of the company’s stock, valued at $8,796,912. The trade was a 8.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.